- Viking Therapeutics (VKTX, Financial) is expected to report first-quarter earnings with a predicted loss of $0.31 per share, reflecting a year-over-year decline.
- Analysts have revised EPS estimates downward four times in the past three months.
- The consensus among 18 brokerage firms suggests an "Outperform" status for Viking Therapeutics.
Upcoming Earnings Release
Viking Therapeutics (NASDAQ: VKTX) is poised to announce its first-quarter earnings on April 23rd after the market closes. Current forecasts by analysts suggest a loss of $0.31 per share, indicating a 19.2% decline compared to the same quarter last year. This estimate reflects a challenging outlook for the company as it has been adjusted downward four times over the past three months.
Analyst Price Targets and Recommendations
According to projections from 15 analysts, the average one-year price target for Viking Therapeutics Inc (VKTX, Financial) is set at $97.40. This suggests a potential upside of 282.26% from the current price of $25.48, with a high estimate reaching $164.00 and a low estimate at $30.00. Investors interested in more specifics can visit the Viking Therapeutics Inc (VKTX) Forecast page.
The consensus rating from 18 brokerage firms presents Viking Therapeutics Inc (VKTX, Financial) with an average recommendation of 1.7, signifying an "Outperform" status. Within the rating scale of 1 to 5, where 1 is a Strong Buy and 5 is a Sell, this reflects a positive outlook on the stock's performance.
Conclusion
As Viking Therapeutics prepares to release its quarterly earnings, the market remains cautiously optimistic despite the recent downward revisions in EPS estimates. The "Outperform" consensus and significant potential upside in price targets underscore the promising prospects perceived by analysts. Investors will be keenly watching how the company's results align with these expectations.
